Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31732993 | 1.00 | GABRA1 (0.48) | GABRA1GABRB2ELANEDAOCYP2C19 | |
| SCHEMBL3244580 | 0.89 | GABRA1 (0.52) | GABRA1GABRB2ELANEDAOHTR2A | |
| SCHEMBL29384962 | 0.89 | CYP1A2 (0.45) | CYP2C19HTR2AALDH1A1PDCD1CD274 | |
| SCHEMBL27015 | 0.89 | CYP1A2 (0.45) | CYP2C19HTR2AALDH1A1PDCD1CD274 | |
| SCHEMBL31733100 | 0.83 | HTR2A (0.44) | GABRA1GABRB2ELANEDAOCYP2C19 | |
| SCHEMBL7885384 | 0.79 | TDP1 (0.36) | GABRA1GABRB2CYP2C19HTR2AALDH1A1 | |
| SCHEMBL3960209 | 0.78 | HTR2A (0.59) | GABRA1GABRB2ELANEDAOHTR2A | |
| SCHEMBL3834629 | 0.78 | ALDH1A1 (0.43) | CYP2C19HTR2AALDH1A1PDCD1CD274 | |
| SCHEMBL7930885 | 0.78 | HTR2A (0.42) | CYP2C19HTR2AALDH1A1PDCD1CD274 | |
| SCHEMBL15345342 | 0.78 | GABRA1 (0.43) | GABRA1GABRB2ELANEDAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2173719-A1 | 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687811-A | 4-imidazolines and as the application of antidepressive | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003867-A1 | 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003867-A1 | 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012138-A1 | 4-IMIDAZOLINES | TAAR1, TAAR5, GPR119 | GABRA1 78/4885GABRB2 123/4885ELANE 4843/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | GABRA1 270/4885GABRB2 119/4885ELANE 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.